1 ld female who presented with infertility and dysmenorrhea.

2 .11 cm [95% CI, -0.50 to 0.29 cm]; P = .60), dysmenorrhea (-0.09 cm [95% CI, -0.49 to 0.30 cm]; P = .

3  usually turn to their PCP for evaluation of dysmenorrhea and CPP.

4 ale who presented with a one-year history of dysmenorrhea and cyclic pelvic pain.

5  2 was a 14-year-old girl who presented with dysmenorrhea and lower abdominal pain since a few months

6 oses of elagolix were effective in improving dysmenorrhea and nonmenstrual pelvic pain during a 6-mon

7                The responses with respect to dysmenorrhea and nonmenstrual pelvic pain were sustained

8 HWW syndrome presenting with regular menses, dysmenorrhea and painful lump in hypogastric region on t

9 ic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain.

10  who had a clinical response with respect to dysmenorrhea and the proportion who had a clinical respo

11 manage, and refer as needed adolescents with dysmenorrhea and/or chronic pelvic pain (CPP) who are su

12 rning the 3 types of pain (noncyclical pain, dysmenorrhea, and dyspareunia) were analyzed separately

13     The most common presentation is pain and dysmenorrhea, and pain and abdominal mass in the lower a

14 onnaire and visual analogue scales (VAS) for dysmenorrhea, chronic pelvic pain, and deep dyspareunia

15 LUNA did not result in improvements in pain, dysmenorrhea, dyspareunia, or quality of life compared w

16                                      Primary dysmenorrhea (PDM), a significant public health problem

17  who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group

18 ation site reactions, breast discomfort, and dysmenorrhea were significantly more common in the patch